Time for more cash

Biotech bankers re-familiarized themselves with the SEC last week, filing to carve $288.6 million out of the financing pie in three sizeable deals. Companies looking for funding include PathoGenesis (PGNS); Vertex (VRTX); and Human Genome Sciences (HGSI). Using Friday's closing prices, VRTX would get the biggest piece - $115.6 million - in its 2.5 million share deal. HGSI would gross $114 million in its 3 million share deal. PGNS would snare $59 million. VRTX is re-dipping the equity ladle only seven months after raising $83 million in a 3 million-share follow-in August. Even though VRTX was off $3.50

Read the full 980 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE